Emyria has today released its quarterly report for the period ending 31st December 2023.
Key highlights for the period include:
- Initiated dosing in a world-first, community-based MDMA-Assisted Therapy Program, which is evaluating a unique MDMA-assisted therapy model for Post-Traumatic Stress Disorder (PTSD)
- Strengthened the board with the appointment of Greg Hutchinson to Independent Chair
- Extended development agreement with the University of Western Australia to create novel and proprietary MDMA analogues with the potential to become treatments for a range of mental health and neurological conditions.
